Advertisement
Screener

Faeth Therapeutics, Inc. (FTH) Graph

FTH Revenue Flow

A current filed revenue breakdown could not be established from the retained filing evidence.

  • 2026-06-30: Research and development (m); Operating expenses $18.39M; Income tax $0.00; Net income -$16.01M.
  • 2026-03-31: Research and development (m); Operating expenses $170.63M; Income tax $0.00; Net income -$170.24M.
  • 2025-12-31: Research and development (m); Operating expenses $4.96M*; Income tax $0.00*; Net income -$4.72M*.
  • 2025-09-30: Research and development (m); Operating expenses $4.85M; Income tax (m); Net income -$4.57M.

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endResearch and developmentOperating expensesIncome taxNet income
2026-06-30(m)$18.39M$0.00-$16.01M
2026-03-31(m)$170.63M$0.00-$170.24M
2025-12-31(m)$4.96M*$0.00*-$4.72M*
2025-09-30(m)$4.85M(m)-$4.57M
2025-06-30(m)$5.21M$0.00-$4.94M
2025-03-31(m)$7.27M$0.00-$6.86M
2024-09-30(m)$7.82M(m)-$7.25M
2024-06-30(m)$7.79M(m)-$7.14M
2024-03-31(m)$8.73M$0.00-$7.99M
2023-09-30(m)$7.74M(m)-$7.12M
2023-06-30(m)$10.18M(m)-$9.39M
2023-03-31(m)$11.01M$0.00-$10.18M
2022-09-30(m)$13.94M(m)-$13.42M
2022-06-30(m)$10.71M(m)-$10.54M
2022-03-31(m)$12.49M$0.00-$12.40M
2021-09-30(m)$10.32M$0.00-$9.69M
2021-06-30(m)$9.78M$0.00-$9.77M
2021-03-31$3.37M$7.97M$0.00-$7.97M
2020-09-30(m)$5.36M$0.00-$5.37M
2020-06-30(m)$4.91M$0.00-$4.91M
2020-03-31$2.19M$4.10M$0.00-$4.69M

Revenue and expense 6 month

Period endOperating expensesIncome taxNet income
2026-06-30$189.01M$0.00-$186.24M
2025-06-30$12.48M$0.00-$11.80M
2024-06-30$16.52M$0.00-$15.13M
2023-06-30$21.18M$0.00-$19.56M
2022-06-30$23.20M$0.00-$22.94M
2021-06-30$17.75M$0.00-$17.74M
2020-06-30$9.01M$0.00-$9.60M

Revenue and expense 9 month

Period endOperating expensesIncome taxNet income
2025-09-30$17.33M$0.00-$16.37M
2024-09-30$24.34M$0.00-$22.39M
2023-09-30$28.92M$0.00-$26.69M
2022-09-30$37.14M$0.00-$36.36M
2021-09-30$28.07M$0.00-$27.43M
2020-09-30$14.37M$0.00-$14.97M

Revenue and expense 12 month

Period endOperating expensesIncome taxNet income
2025-12-31$22.29M$0.00-$21.09M
2024-12-31$32.61M$0.00-$30.16M
2023-12-31$37.06M(m)-$34.10M
2022-12-31$50.19M(m)-$48.59M
2021-12-31$37.48M(m)-$36.79M
2020-12-31$19.45M(m)-$20.10M

Similar stocks

Stock NameCountryMarket CapPE Ratio
COLLEGIUM PHARMACEUTICAL, INC (COLL)United States$0.737B24.57
Design Therapeutics, Inc. (DSGN)United States$0.766B-12.78
Wave Life Sciences, Inc. (WVE)$0.780B-5.56
Olema Pharmaceuticals, Inc. (OLMA)United States$0.790B-5.35
Aclaris Therapeutics, Inc. (ACRS)United States$0.792B-9.78
Verastem, Inc. (VSTM)United States$0.706B-1.71
Nuvectis Pharma, Inc. (NVCT)United States$0.705B-17.53
GERON CORP (GERN)United States$0.803B-12.14
IRONWOOD PHARMACEUTICALS INC (IRWD)United States$0.694B5.37
Climb Bio, Inc. (CLYM)United States$0.683B-13.03